Prelude Capital Management, LLC Dynavax Technologies Corp Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$2.27 - $6.2 $1,003 - $2,740	-442 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$3.46 - $6.93 $152 - $304	-44 Reduced 9.05%	442 $3,000
Q3 2019 Nov 14, 2019	BUY	$2.69 - $4.85 $1,307 - $2,357	486 New	486 $2,000
Q2 2019 Aug 14, 2019	SELL	$3.65 - $7.89 $2,069 - $4,473	-567 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.08 - $12.09 $1,947 - $3,324	275 Added 94.18%	567 $4,000
Q4 2018 Feb 14, 2019	BUY	$8.14 - $13.28 $2,376 - $3,877	292 New	292 $3,000
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $43,250 - $60,199	-2,500 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$15.2 - $21.5 $38,000 - $53,750	2,500	2,500 $54,000

259

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.42B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.